{"id":52745,"date":"2023-01-10T13:01:38","date_gmt":"2023-01-10T12:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/"},"modified":"2023-01-10T13:01:38","modified_gmt":"2023-01-10T12:01:38","slug":"forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/","title":{"rendered":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership"},"content":{"rendered":"
\n

\nForge to provide manufacturing and development services for<\/i> Oculogenex\u2019s novel AAV gene therapy to improve vision in patients with macular degeneration<\/i>\n<\/p>\n

LA HABRA, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to stop the degeneration of central vision in patients, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership to help support the advancement of Oculogenex\u2019s gene therapy program for dry age-related macular degeneration (AMD) toward clinical trials.\n<\/p>\n

<\/a><\/p>\n

\nForge will provide AAV process and analytical development, and manufacturing services for Oculogenex. The program will utilize Forge\u2019s platform process, including its proprietary HEK 293 suspension Ignition\u2122 cell line and pEMBR\u2122 adenovirus helper plasmid. All AAV development and manufacturing activities will occur at the Hearth, Forge\u2019s 200,000 square foot gene therapy cGMP production facility in Columbus, Ohio.\n<\/p>\n

\n\u201cWe are excited to announce our partnership supporting Oculogenex\u2019s efforts in developing a gene therapy that has the potential to dramatically change and improve the quality of life for patients suffering from dry AMD,\u201d said John Maslowski, Chief Commercial Officer of Forge Biologics. \u201cTheir work is incredibly important to patients, and we look forward to delivering the resources and scale as their preferred AAV manufacturing partner on this endeavor.\u201d\n<\/p>\n

\nOculogenex\u2019s investigational approach is a novel ocular regenerative AAV gene therapy that is delivered as a one-time injection into the eye. Preclinical data demonstrate that this approach makes retinal cells more resistant to stress, helps cells repair damage, and increases the cells\u2019 lifespans. The approach has the potential to activate dormant stem cells in the retina to replace lost tissue. Post-administration benefits have been demonstrated in preclinical research, and the company is completing additional preclinical research to prepare for entry into Phase I clinical trials.\n<\/p>\n

\n\u201cWe started this company because there were no treatments available for patients with dry age-related macular degeneration,\u201d said Hema Ramkumar, M.D., CEO and Founder of Oculogenex. \u201cI am thrilled to be partnering with Forge to be able to offer better options to these patients, with promise for other patients living with degenerative blinding retinal diseases.\u201d\n<\/p>\n

\nAbout Age-Related Macular Degeneration<\/b>\n<\/p>\n

\nAge-related macular degeneration (AMD) is the leading cause of irreversible vision loss in patients over 60 in the United States and a leading cause of vision loss in the world. Patients with early forms of the disease may see wavy lines or distorted vision and have difficulty seeing and reading. Those affected by advanced disease have loss of central vision and cannot see the object they are trying to focus on. For elderly patients, the inability to read correlates with loss of independence, disability, depression, increased risk of falls, and mortality. Advanced age-related macular degeneration is either geographic atrophy (the dry type) or wet macular degeneration, which is treated with frequent injection therapy. There are no current treatments for dry age-related macular degeneration.\n<\/p>\n

\nAbout Oculogenex<\/b>\n<\/p>\n

\nOculogenex is a biotech company utilizing gene therapy to improve vision in patients with degenerative retinal diseases. The California-based company is developing a gene therapy treatment to stop the degeneration of central vision in patients with age-related macular degeneration. The therapy has the potential to dramatically improve the quality of life of patients living with blinding retinal diseases and no treatment options. To learn more, visit www.oculogenex.com<\/a>.\n<\/p>\n

\nAbout Forge Biologics<\/b>\n<\/p>\n

\nForge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge\u2019s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge\u2019s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Inquiries\u2014Forge Biologics<\/b>
Marina Corleto
\n
Associate Director, Marketing and Communications
\n
media@forgebiologics.com<\/a>\n<\/p>\n

\nMedia Inquiries\u2014Oculogenex<\/b>
Ram Ramkumar, Ph.D.
\n
ram@oculogenex.com<\/a>\n<\/p>\n

\nClient Development\u2014Forge Biologics<\/b>
John Maslowski
\n
Chief Commercial Officer
\n
CD@forgebiologics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Forge to provide manufacturing and development services for Oculogenex\u2019s novel AAV gene therapy to improve vision in patients with macular degeneration LA HABRA, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to stop the degeneration of central vision in patients, and Forge Biologics, a gene therapy-focused … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52745","6":"format-standard","7":"category-industry"},"yoast_head":"\nForge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Forge to provide manufacturing and development services for Oculogenex\u2019s novel AAV gene therapy to improve vision in patients with macular degeneration LA HABRA, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to stop the degeneration of central vision in patients, and Forge Biologics, a gene therapy-focused ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-10T12:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership\",\"datePublished\":\"2023-01-10T12:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/\"},\"wordCount\":735,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005476\\\/en\\\/1609655\\\/21\\\/Forge_Biologics_Primary_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/\",\"name\":\"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005476\\\/en\\\/1609655\\\/21\\\/Forge_Biologics_Primary_Logo.jpg\",\"datePublished\":\"2023-01-10T12:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005476\\\/en\\\/1609655\\\/21\\\/Forge_Biologics_Primary_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005476\\\/en\\\/1609655\\\/21\\\/Forge_Biologics_Primary_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/","og_locale":"en_US","og_type":"article","og_title":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend","og_description":"Forge to provide manufacturing and development services for Oculogenex\u2019s novel AAV gene therapy to improve vision in patients with macular degeneration LA HABRA, Calif. & COLUMBUS, Ohio–(BUSINESS WIRE)–Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to stop the degeneration of central vision in patients, and Forge Biologics, a gene therapy-focused ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-10T12:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership","datePublished":"2023-01-10T12:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/"},"wordCount":735,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/","url":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/","name":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg","datePublished":"2023-01-10T12:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230110005476\/en\/1609655\/21\/Forge_Biologics_Primary_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/forge-biologics-and-oculogenex-announce-aav-contract-development-and-manufacturing-partnership\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52745"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52745\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}